SPATA19 and neoplasm: There was also no impact of anti-PD-1, anti-PD-L1, or anti-CTLA-4 ICI therapy on the frequency of CD8+ SPAS-1+ T cells in tumor following any of the ICI therapy regimens (Supplementary Fig. 2b).